Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications-Reference-Cited by-同舟云学术

Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications

Published:2022-12-12 Issue:1 Volume:16 Page:27-38
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Galli Mattia¹²^ORCID,Franchi Francesco³,Rollini Fabiana³,Ortega-Paz Luis³,D’Amario Domenico⁴,De Caterina Raffaele⁵⁶^ORCID,Mehran Roxana⁷,Gibson C Michael⁸,Angiolillo Dominick J.³^ORCID

Affiliation:

1. Catholic University of the Sacred Heart, Rome, Italy

2. Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy

3. Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States

4. Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

5. University of Pisa and University Cardiology Division, Pisa University Hospital, Pisa, Italy

6. Fondazione VillaSerena per la Ricerca, Città Sant’Angelo, Pescara, Italy

7. Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

8. Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2023.2154651

Reference57 articles.

1. World Health Organization. WHO mortality database. https://www.who.int/data/data-collection-tools/who-mortality-database.

2. Atherosclerosis

3. Management of Antithrombotic Therapy after Acute Coronary Syndromes

4. Antiplatelet therapy after percutaneous coronary intervention

5. Low-Dose Aspirin for the Prevention of Atherothrombosis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Potential of FXI Inhibitors: Hype or Hope?;Drugs;2024-07-29

2. Reevaluating Anticoagulation in Antiphospholipid Syndrome: The Role of Apixaban in the Current Treatment Paradigm;Journal of Cardiovascular Pharmacology;2024-07

3. Editorial: Novel and potential biomarkers for prediction of outcome in patients with chronic and acute coronary heart disease, volume II;Frontiers in Cardiovascular Medicine;2024-05-28

4. P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC–2 Study;JACC: Cardiovascular Interventions;2024-04

5. Pan-vascular disease: what we have done in the past and what we can do in the future?;Cardiology Plus;2024-03-08